Bayesian Toxicity Risk Modeling for Personalized Radiation Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiation therapy planning methods fail to account for significant inter-patient variability in side effects, relying on historical population data to determine normal tissue dose constraints, leading to suboptimal treatment plans and increased side effects.
Innovation Solution
Utilizing a Bayesian network-based model that incorporates patient-specific biomarker data to estimate and dynamically update toxicity risk during radiation therapy, providing a graphical user interface for clinicians to adjust treatment plans accordingly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If historical population data is used to determine normal tissue dose constraints, then treatment planning can be standardized and simplified, but inter-patient variability in side effects is not accounted for leading to suboptimal treatment plans
Solution Approach 1:
The patent transforms fixed population-based dose constraints into dynamic, patient-specific constraints by changing the parameters used in NTCP models. Instead of applying universal dose limits, the system adjusts dose constraints based on individual patient biomarkers, genetic profiles, and real-time treatment response data, thereby resolving the contradiction between standardization and personalization.
Solution Approach 2:
The system enables self-service by allowing the treatment plan to automatically adapt to each patient's unique characteristics without requiring manual customization by planners. The NTCP models continuously update toxicity predictions based on patient-specific data, automatically adjusting dose constraints and treatment parameters to optimize outcomes for each individual patient.
2Reliability
If maximal radiation dose is delivered to the tumor to increase sterilization probability, then tumor control improves, but normal tissue complications increase
Solution Approach 1:
The patent applies local quality by differentiating between tumor tissue and normal tissue responses to radiation. The system uses patient-specific NTCP models to determine optimal dose constraints for different normal tissues based on their individual sensitivity characteristics, allowing maximal tumor dose delivery while protecting specific normal tissues that are most vulnerable for each patient.
Solution Approach 2:
The system implements feedback mechanisms where real-time monitoring of patient response during treatment allows continuous adjustment of the treatment plan. Biomarker changes and treatment response data feed back into the NTCP models, which then adjust dose constraints and treatment parameters to maintain tumor control while preventing normal tissue complications.
3Productivity
If population-based NTCP models are used for all patients, then treatment planning is efficient and quick, but individual patient toxicity risks are not accurately predicted
Solution Approach 1:
The patent transforms static, population-based NTCP models into dynamic, patient-specific models. The system continuously updates toxicity predictions during treatment based on individual patient biomarkers and response data, allowing the NTCP models to adapt and evolve for each patient rather than applying fixed population averages, thereby maintaining efficiency while improving prediction accuracy.
Data Source
AI summary
In providing radiation therapy (RT) support, a patient specific toxicity risk is estimated for a RT side effect using a Bayesian network that receives as inputs values of biomarkers of the patient. A patient-specific RT plan is optimized with respect to parameters including the patient-specific toxicity risk. During delivery of RT according to the plan, at least one updated value is received for the biomarkers of the patient, and an updated patient-specific toxicity risk is estimated using the Bayesian network with the updated value(s). The Bayesian network biomarker nodes and a toxicity risk node representing the patient specific toxicity risk, and directed arcs with arc weights representing strengths of interdependencies between the nodes connected by the directed arcs. A graphical user interface (GUI) is provided via which a clinician may interact with the Bayesian network. A test recommendation may be initiated or updated for scheduling of a patient test based on the updated patient-specific toxicity risk.